Stockscreener 앱 받기
1.43
5.15%
0.07
시간 외 거래:
1.39
-0.04
-2.80%
전일 마감가:
$1.36
열려 있는:
$1.37
하루 거래량:
185.48K
Relative Volume:
0.17
시가총액:
$89.85M
수익:
$13.86M
순이익/손실:
$-79.62M
주가수익비율:
-1.1141
EPS:
-1.2835
순현금흐름:
$-63.51M
1주 성능:
-6.54%
1개월 성능:
-5.92%
6개월 성능:
-30.58%
1년 성능:
+24.35%
1일 변동 폭
$1.36
$1.46
1주일 범위
$1.35
$1.575
52주 변동 폭
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
명칭
Pyxis Oncology Inc
전화
(617) 221-9059
주소
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.43 | 85.45M | 13.86M | -79.62M | -63.51M | -1.2835 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Stifel | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-11-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-08-08 | 개시 | Stifel | Buy |
| 2024-05-07 | 재개 | Jefferies | Buy |
| 2024-02-09 | 개시 | BTIG Research | Buy |
| 2024-01-23 | 개시 | Leerink Partners | Outperform |
| 2023-09-05 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-02 | 개시 | BofA Securities | Neutral |
| 2021-11-02 | 개시 | Credit Suisse | Outperform |
| 2021-11-02 | 개시 | Jefferies | Buy |
모두보기
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com Australia
Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike - Stock Titan
Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options - Stock Titan
Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants - Stock Titan
Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com
Pyxis Oncology (PYXS) director receives grant of 45,867 stock options - Stock Titan
[Form 4] Pyxis Oncology, Inc. Insider T... - Stock Titan
Director at Pyxis Oncology (PYXS) receives grant of 45,867 stock options - Stock Titan
Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares - MarketBeat
Pyxis Oncology (PYXS) director sells 15,496 shares under 10b5-1 plan - Stock Titan
FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst - MarketBeat
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo
Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00 - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Given Buy Rating at HC Wainwright - MarketBeat
Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target - Investing.com
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
RBC Capital Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $5 - Moomoo
Stifel cuts Pyxis Oncology stock price target on financing assumptions - Investing.com
Pyxis Oncology Reports 2025 Financial Results, Advances MICVO Cancer Trials, and Announces New Leadership - Minichart
William Blair reiterates Pyxis Oncology stock rating on trial pace - Investing.com UK
Jefferies raises Pyxis Oncology stock price target on drug data By Investing.com - Investing.com Australia
Jefferies raises Pyxis Oncology stock price target on drug data - Investing.com
MicuRx Pharmaceuticals: Advancing Novel ADC Therapy MICVO for Difficult-to-Treat Head and Neck Cancer – Pipeline, Strategy, and Risks Overview - Minichart
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Pyxis Oncology Reports Q4 Results, Advances MICVO Program - TipRanks
Pyxis Oncology 10-K: Revenue $13.9M; Net loss $(79.6)M - TradingView
Pyxis Oncology (PYXS) highlights MICVO ADC progress in head and neck cancer - Stock Titan
Pyxis Oncology (NASDAQ: PYXS) details 2025 results and MICVO head & neck cancer data - Stock Titan
Pyxis Oncology 2025 net loss widens on higher R&D spend - TradingView
BRIEF-Pyxis Oncology FY Net Income USD -79.621 Million - TradingView
Pyxis fills head and neck cancer study, says cash lasts into Q4 - Stock Titan
PYXS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Pyxis Oncology Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen - Defense World
Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen - MarketBeat
PYXS Technical Analysis & ETF Price Forecast - Intellectia AI
Will Pyxis Oncology Inc stock benefit from M A2025 Growth vs Value & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
PYXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Pyxis Oncology Inc. expand its profit marginsWeekly Trade Review & Low Drawdown Investment Ideas - mfd.ru
PYXS Should I Buy - Intellectia AI
Can Pyxis Oncology Inc. stock hit record highs againWeekly Risk Report & AI Powered Buy/Sell Recommendations - mfd.ru
Street Watch: Can Pyxis Oncology Inc sustain its profitabilityJuly 2025 News Drivers & Fast Gain Stock Tips - baoquankhu1.vn
Pyxis Oncology Inc (PYXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):